| 货号 | CAS号 |
|---|---|
| G129772-250mg | 317318-70-0 |
| G129772-25mg | 317318-70-0 |
| G129772-50mg | 317318-70-0 |
| G129772-5mg | 317318-70-0 |
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
| 产品介绍 |
{2- |
| 备注 | GW501516 is a potent and highly selective PPARβ/δ agonist, with EC50 of 1 nM, with 1000-fold selectivity over hPPARα and hPPARγ. Phase 4. |
| 生化机理 |
GW501516 (GW1516 or GSK-516) is a drug that acts as a PPARδ modulator. GW 501516 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in animal studies. |
| 别名 | GW1516, GSK-516, GW-501516;2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid;GW1516, GSK-516, GW-501516;2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy)acetic acid |
